Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
顯示更多
執行長
Stephen Dilly
員工
69
國家
美國
ISIN
US82640U4040
上市
0 則留言
分享你的想法
常見問題
Sierra Oncology 今天的股價是多少?▼
SRRA 目前價格為 $54.99 USD,過去 24 小時上漲了 +0.04%。在圖表上更密切關注 Sierra Oncology 股價表現。